Unternehmen Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG
Aktien
A12BXW
US10501E2019
GHDN
Biotechnologie
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
0.4685 EUR | +0.64% | +8.57% | +103.70% |
Kurzporträt
Mitarbeiterzahl: 29
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 53 | 01.07.07 |
Alla Patlis
DFI | Director of Finance/CFO | 37 | 23.12.12 |
Chief Tech/Sci/R&D Officer | - | 12.05.22 | |
Bob Dagher
CTO | Chief Tech/Sci/R&D Officer | 55 | 17.07.23 |
Yael Gothelf
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.07 |
Stacy Lindborg
BRD | Director/Board Member | 53 | 01.06.20 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06.06.14 |
General Counsel | - | 12.05.22 | |
Mary Kay Turner
LAW | General Counsel | - | 07.08.17 |
Yossef Levy
PRN | Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Irit Arbel
FOU | Founder | 64 | 22.09.00 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06.06.14 |
Jacob Frenkel
CHM | Chairman | 81 | 30.03.20 |
Director/Board Member | 63 | 28.10.21 | |
Director/Board Member | 61 | 05.02.18 | |
Stacy Lindborg
BRD | Director/Board Member | 53 | 01.06.20 |
Nir Naor
BRD | Director/Board Member | 50 | 20.06.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 70 080 523 | 60 766 674 ( 86,71 %) | 0 | 86,71 % |
Unternehmenskontakt
Brainstorm Cell Therapeutics, Inc.
1325 Avenue of Americas 28th floor
10019, New York
+201 488 0460
http://www.brainstorm-cell.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+41.79% | 50.93 Mrd. | |
-0.56% | 42.12 Mrd. | |
+49.62% | 42.05 Mrd. | |
-7.20% | 29.18 Mrd. | |
+12.59% | 26.02 Mrd. | |
-21.51% | 18.9 Mrd. | |
+6.92% | 13.21 Mrd. | |
+24.91% | 12.17 Mrd. | |
+29.60% | 12.16 Mrd. |
- Börse
- Aktien
- A12BXW Aktie
- A12BXW Aktie
- Unternehmen Brainstorm Cell Therapeutics Inc.